Merck halts Phase III trial of AD candidate verubecestat

Merck & Co. Inc. (NYSE:MRK) stopped the double-blind, international Phase III APECS trial of verubecestat (MK-8931) to treat prodromal Alzheimer’s disease after an external DMC said it was unlikely the trial would establish a positive

Read the full 354 word article

User Sign In